(A) reacting the alkali metal salt of 2, 6-dichlorpurine with a 2-desoxy-3, 5 -di-O-p-toluoyl-alpha-D-erythro-pentofuranose or a derivative thereof, in a suitable organic solvent, said reaction optionally being carried out in the presence of a Lewis-acid, whereby a mixture comprising the intermediate N (9) -beta-compound, the N (7) -beta-regio- isomer, and the N (9) -alpha-stereoisomer is formed; (B) isolating from said reaction mixture formed the crude reaction product comprising the intermediate N (9) -beta- compound by a purification method, preferably by precipitation or crystallization, using a suitable organic solvent or a mixture of such organic solvents or a mixture of one or more of such organic solvents with water, without using a chromatographic purification method, and (C) subjecting the isolated intermediate N (9 ) -beta-compound to ammonolysis, where upon the 2 '-deoxyadenosine compound is formed, and (D) precipitating or crystallizing the 2 '-deoxyadenosine compound as formed in step (C) from a suitable organic solvent.
(A) 使
2,6-二氯嘌呤的碱
金属盐与2-去氧-3,5-二-O-p-
甲苯酰基-α-D-赤 trựcофuranose或其衍
生物在合适的有机溶剂中反应,该反应可选在
路易斯酸存在下进行,从而形成包含中间体N(9)-β化合物、N(7)-β区域异构体和N(9)-α旋光异构体的混合物;
(B) 通过净化方法(优选为沉淀或结晶)从上述反应混合物中分离出包含中间体N(9)-β化合物的粗反应产物,使用合适的有机溶剂或多种此类有机溶剂的混合物,或一种或多种此类有机溶剂与
水的混合物,且不使用色谱净化方法;
(C) 将分离得到的中间体N(9)-β化合物进行
氨解,从而生成2’-去氧
腺苷化合物;以及
(D) 将步骤(C)中生成的2’-去氧
腺苷化合物从合适的有机溶剂中沉淀或结晶。